ReviewVaccine2013
Chlamydia trachomatis control requires a vaccine.
Review in Vaccine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed.
- Seroprevalence of antibodies against Pkn1, a novel potential immunogen, in Chlamydia trachomatis-infected Macaca nemestrina and human patients.BioMed research international · 2014Trial
- CXCR6 marks polyfunctional effector CD4 T cells required for anti-bioRxiv : the preprint server for biology · 2026Article
- Chlamydia trachomatis-specific T Cell Immunity Reflects Widespread Exposure in South African Adolescents and Young Women.The Journal of infectious diseases · 2026Article
- Vaccination as a strategy for Chlamydia trachomatis control: a global mathematical modeling analysis.BMC global and public health · 2025Article
- Viral Vector-BasedVaccines · 2024Article
- Addressing Challenges inMedicina (Kaunas, Lithuania) · 2024Review
- Impact of a potential Chlamydia vaccine in the USA: mathematical modelling analyses.BMJ public health · 2024Article
- In silico design and analysis of a multiepitope vaccine against Chlamydia.Pathogens and disease · 2024Article
- Prophylactic and therapeutic vaccination protects sperm health from Chlamydia muridarum-induced abnormalities.Biology of reproduction · 2023Article
- Association between serumFrontiers in public health · 2023Article
- Therapeutic Options forAntibiotics (Basel, Switzerland) · 2022Review
- DnaJ, a promising vaccine candidate against Ureaplasma urealyticum infection.Applied microbiology and biotechnology · 2022Article
- Overexpression of the Bam Complex Improves the Production ofInternational journal of molecular sciences · 2022Article
- Results from a large cross-sectional study assessing Chlamydia trachomatis, Ureaplasma spp. and Mycoplasma hominis urogenital infections in patients with primary infertility.Scientific reports · 2021Article
- Prophylactic Multi-Subunit Vaccine againstVaccines · 2021Article
- Encapsulation of Recombinant MOMP in Extended-Releasing PLGA 85:15 Nanoparticles Confer Protective Immunity Against aFrontiers in immunology · 2021Article
- Protection of outbred mice against a vaginal challenge by aHuman vaccines & immunotherapeutics · 2020Article
- Vaccination with the recombinant major outer membrane protein elicits long-term protection in mice against vaginal shedding and infertility following aNPJ vaccines · 2020Article
- Characterization of the Horizontal and Vertical Sexual Transmission ofInfection and immunity · 2019Article
- Does infection withSexually transmitted infections · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
As the most common reported communicable disease in North America and Europe, Chlamydia trachomatis is the focus of concerted public health control efforts based on screening and treatment. Unexpectedly control efforts are accompanied by rising reinfection rates attributed in part to arresting the development of herd immunity. Shortening the duration of infection through the testing and treatment program is the root cause behind the arrested immunity hypothesis and because of this a vaccine will be essential to control efforts. Advances in Chlamydia vaccinomics have revealed the C. trachomatis antigens that can be used to constitute a subunit vaccine and a vaccine solution appears to be scientifically achievable. We propose that an accelerated C. trachomatis vaccine effort requires coordinated partnership among academic, public health and private sector players together with a commitment to C. trachomatis vaccine control as a global public health priority.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.